Status
Conditions
Treatments
About
This is a prospective, open-label, multi-center, non-comparative study that will be conducted on female subjects between 30 and 75 years of age, diagnosed with stress urinary incontinence (SUI).
Following the screening period, including urodynamic assessment to confirm SUI, each subject will undergo three FemiLiftTM treatment sessions, and will be followed up for a period of one year. The main efficacy endpoint in this study is defined as significant improvement (score of 6 or 7) in the urinary incontinence measured with PGI-I score at the 6 months visit. Various subjective and objective measures of incontinence severity, quality of life, sexual function and tissue effects will be performed at follow up.
Full description
Improvement in SUI symptoms as measured by the following parameters:
Objective parameters:
Change from baseline in 3 days Urinary Diary - at 1, 2, 6 and 12 months:
Change from baseline in 1 hour pad test 1, 2, 6 and 12 months
Change from baseline as assessed with Vaginal Biopsy
Subjective parameters:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
60 participants in 1 patient group
Loading...
Central trial contact
Yair Leopld
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal